Vis børsmeldingen
increasing share of manufacturing and testing activities consolidated at the
Company’s Bergen facilities.
Nine implants that successfully completed pressure and electronic
qualification testing in Bergen were shipped to Lifecare’s Bristol operations
on 20 October for end-of-line testing.
A further production batch was completed on 24 October, with eight implants
successfully completing the applicable qualification testing in Bergen.
The latest production activity follows Lifecare’s announcement on 29 September
2026 of the first successful in-house production of functional CGM implants in
Bergen. That initial batch consisted of three implants, of which two
successfully completed testing.
Within less than one month, Lifecare has progressed from its first three-units
produced in Bergen to successive production runs yielding a total of 19
implants successfully completing qualification testing.
“We are seeing a solid and rapid development in our manufacturing capability.
Less than a month ago, we communicated the first functional implants
manufactured in Bergen. Since then, we have moved into substantially larger
and successive production runs,” says Joacim Holter, CEO of Lifecare.
“We are establishing the capability for a repeatable production rhythm and
demonstrating that the manufacturing process can be repeated across successive
batches at materially higher volumes.”
The first functional implants communicated 29 September were produced on
Lifecare’s temporary production line in Bergen. The subsequent production
batches have been manufactured at the Company’s new facilities following the
acquisition of Ocean Tunicell AS. The new facilities bring together dedicated
production and laboratory infrastructure, increased space and technical
personnel, and have enabled a more efficient manufacturing workflow and higher
production volumes.
Final operational step in consolidating implant manufacturing in Bergen
Lifecare is now preparing to transfer end-of-line testing from Bristol to
Bergen, representing the final major operational step in consolidating the
implant manufacturing workflow at the Company’s Bergen facilities.
End-of-line testing was initially established at Lifecare’s specialised
chemistry laboratories in Bristol. The new Bergen facilities now provide the
laboratory infrastructure, production environment and personnel required to
centralise this function alongside implant manufacturing.
Personnel from Bristol will support the transfer and establishment of
end-of-line testing in Bergen. Implants from the latest production batch are
therefore intended to undergo end-of-line testing in Bergen rather than being
shipped to Bristol.
At the same time, Lifecare has increased staffing at Lifecare Chemistry in
Bristol to expand laboratory throughput and development capacity. With
end-of-line testing moving to Bergen, the Bristol team will increasingly focus
on chemistry development, including further product optimisation for glucose
sensitivity and continued development of Lifecare’s osmotic sensing
technology.
“Moving end-of-line testing to Bergen allows us to sharpen the role of both
sites. Bergen is becoming our centre for implant manufacturing and testing,
while Bristol can focus more fully on chemistry innovation,” Holter says.
“The increased capacity at Lifecare Chemistry is intended both to accelerate
optimisation of our glucose sensing chemistry and to give us greater capacity
to investigate the broader platform potential of our sensing technology.”
Glucose remains Lifecare’s primary development focus, while the Company
continues to evaluate the potential of its osmotic sensing principle as a
platform for additional analytes.
Lifecare does not intend to provide market updates on individual production
batches going forward. The current development is considered relevant as the
successive production runs, consolidation of manufacturing and testing in
Bergen, and increased development capacity in Bristol demonstrate material
progression in both manufacturing capability and technology development.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare’s focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare’s sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64
Kilde
